文献速递肝胆胰外科围术期管理与 ERAS

氨甲环酸对胰十二指肠切除术出血的影响:TAC-PD随机临床试验

Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial.
PubMed 文献 · Br J Surg · 2023-01-01

这项实用型多中心随机双盲安慰剂对照试验纳入218例计划行胰十二指肠切除术的成人患者,比较氨甲环酸(TXA)与安慰剂对术中出血的影响。结果显示,TXA组与安慰剂组术中平均出血量分别为659 ml和701 ml(平均差-42 ml,95%CI -191至106),差异无统计学意义。围术期TXA使用并未减少胰十二指肠切除术中的出血。

要点

  • 围术期使用TXA未显著减少胰十二指肠切除术中的出血量。
  • TXA组与安慰剂组术中平均出血量差异为-42 ml(95%CI -191至106)。
  • 两组围术期输血、手术时间、并发症和死亡率等次要结局相当。

核心结论

  • 围术期使用氨甲环酸并未减少胰十二指肠切除术中的出血量。

研究设计与样本

  • 实用型、多中心、随机、盲法、安慰剂对照试验,纳入218例计划行胰十二指肠切除术的成人患者,随机分为TXA组(108例)和安慰剂组(110例)。

主要发现

  • TXA组术中平均出血量为659 ml,安慰剂组为701 ml,平均差-42 ml(95%CI -191至106)。
  • 在202例实际接受干预并完成胰十二指肠切除术的患者中,TXA组平均出血量为667 ml,安慰剂组为744 ml,平均差-77 ml(95%CI -226至72)。
  • 两组次要结局(围术期输血、手术时间、并发症和死亡率)相当。

临床怎么用

  • 对于计划行胰十二指肠切除术的患者,围术期使用氨甲环酸不应以减少术中出血为目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tranexamic acid (TXA) may reduce intraoperative blood loss, but it has not been investigated in pancreaticoduodenectomy (PD). METHODS: A pragmatic, multicentre, randomized, blinded, placebo-controlled trial was conducted. Adult patients undergoing planned PD for biliary, duodenal, or pancreatic diseases were randomly assigned to TXA or placebo groups. Patients in the TXA group were administered 1 g TXA before incision, followed by a maintenance infusion of 125 mg/h TXA. Patients in the placebo group were administered the same volume of saline as those in the placebo group. The primary outcome was blood loss during PD. The secondary outcomes included perioperative blood transfusions, operating time, morbidity, and mortality. RESULTS: Between September 2019 and May 2021, 218 patients were randomly assigned and underwent surgery (108 in the TXA group and 110 in the placebo group). Mean intraoperative blood loss was 659 ml in the TXA group and 701 ml in the placebo group (mean difference -42 ml, 95 per cent c.i. -191 to 106). Of the 218 patients, 202 received the intervention and underwent PD, and the mean blood loss during PD was 667 ml in the TXA group and 744 ml in the placebo group (mean difference -77 ml, 95 per cent c.i. -226 to 72). The secondary outcomes were comparable between the two groups. CONCLUSION: Perioperative TXA use did not reduce blood loss during PD. REGISTRATION NUMBER: jRCTs041190062 (https://jrct.niph.go.jp). Removing part of the pancreas is an operation with a risk of major blood loss. Tranexamic acid is a drug thought to reduce blood loss. This study asked the question, ‘Does tranexamic acid reduce blood loss during surgery on the pancreas?’ Half of patients received tranexamic acid during surgery. The other half received only standard care. This study showed that tranexamic acid did not decrease the blood loss during the surgery and may have little effect in patients having a pancreaticoduodenectomy.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Ishii K, Yokoyama Y, Yonekawa Y, et al. Tranexamic acid and blood loss in pancreaticoduodenectomy: TAC-PD randomized clinical trial. Br J Surg. 2023. PMID: 36379883. doi:10.1093/bjs/znac382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。